Abstract
Machado-Joseph disease (MJD) also known as Spinocerebellar ataxia type 3, is a hereditary neurodegenerative disease associated with severe clinical manifestations and premature death. Although rare, it is the most common autosomal dominant spinocerebellar ataxia worldwide and has a distinct geographic distribution, reaching peak prevalence in certain regions of Brazil, Portugal and China. Due to its clinical heterogeneity, it was initially described as several different entities and as had many designations over the last decades. An accurate diagnosis become possible in 1994, after the identification of the MJD1 gene. Among its wide clinical spectrum, progressive cerebellar ataxia is normally present. Other symptoms include pyramidal syndrome, peripheral neuropathy, oculomotor abnormalities, extrapyramidal signs and sleep disorders. On the basis of the presence/absence of important extra-pyramidal signs, and the presence/absence of peripheral signs, five clinical types have been defined. Neuroimaging studies like MRI, DTI and MRS, can be useful as they can characterize structural and functional differences in specific subgroups of patients with MJD. There is no effective treatment for MJD. Symptomatic therapies are used to relieve some of the clinical symptoms and physiotherapy is also helpful in improving quality of live. Several clinical trials have been carried out using different molecules like sulfamethoxazole-trimethoprim, varenicline and lithium carbonate, but the results of these trials were negative or showed little benefit. Future studies sufficiently powered and adequately designed are warranted.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Romanul FC et al (1977) Azorean disease of the nervous system. N Engl J Med 296(26):1505–1508
Schols L et al (2004) Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol 3(5):291–304
Jardim LB et al (2001) A survey of spinocerebellar ataxia in South Brazil—66 new cases with Machado-Joseph disease, SCA7, SCA8, or unidentified disease-causing mutations. J Neurol 248:870–876
Silveira I et al (1998) Analysis of SCA1, DRPLA, MJD, SCA2, and SCA6 CAG repeats in 48 Portuguese ataxia families. Am J Med Genet 81:134–138
Vale J et al (2010) Autosomal dominant cerebellar ataxia: frequency analysis and clinical characterization of 45 families from Portugal. Eur J Neurol 17(1):124–128
Zhao Y et al (2002) Prevalence and ethnic differences of autosomal-dominant cerebellar ataxia in Singapore. Clin Genet 62:478–481
Tang B et al (2000) Frequence of SCA1, SCA2, SCA3/MJD, SCA6, SCA7, and DRPLA CAG trinucleotide repeat expansion in patients with hereditary spinocerebellar ataxia from Chinese kindreds. Arch Neurol 57:540–544
van de Warrenburg BP et al (2002) Spinocerebellar ataxias in the Netherlands: prevalence and age at onset variance analysis. Neurology 58:702–708
Schols L et al (1997) Autosomal dominant cerebellar ataxia: phenotypic differences in genetically defined subtypes? Ann Neurol 42:924–932
Maruyama H et al (2002) Difference in disease-free survival curve and regional distribution according to subtype of spinocerebellar ataxia: a study of 1,286 Japanese patients. Am J Med Genet 114:578–583
Shibata-Hamaguchi A et al (2009) Prevalence of spinocerebellar degenerations in the Hokuriku district in Japan. Neuroepidemiology 32:176–183
Kraft S et al (2005) Adult onset spinocerebellar ataxia in a Canadian movement disorders clinic. Can J Neurol Sci 32:450–458
Moseley ML et al (1998) Incidence of dominant spinocerebellar and Friedreich triplet repeats among 361 ataxia families. Neurology 51:1666–1671
Alonso E et al (2007) Distinct distribution of autosomal dominant spinocerebellar ataxia in the Mexican population. Mov Disord 22:1050–1053
Storey E et al (2000) Frequency of spinocerebellar ataxia types 1, 2, 3, 6, and 7 in Australian patients with spinocerebellar ataxia. Am J Med Genet 95:351–357
Saleem Q et al (2000) Molecular analysis of autosomal dominant hereditary ataxias in the Indian population: high frequency of SCA2 and evidence for a common founder mutation. Hum Genet 106:179–187
Bryer A et al (2003) The hereditary adult-onset ataxias in South adult-onset ataxias in South Africa. J Neurol Sci 216:47–54
Brusco A et al (2004) Molecular genetics of hereditary spinocerebellar ataxia: mutation analysis of spinocerebellar ataxia genes and CAG/CTG repeat expansion detection in 225 Italian families. Arch Neurol 61:727–733
Coutinho P (1992) Doença de Machado-Joseph: Tentativa de definição. Ph.D. Dissertation, Instituto de Ciências Biomédicas Abel Salazar, Porto
Maciel P et al (2001) Improvement in the molecular diagnosis of Machado-Joseph disease. Arch Neurol 58:1821–1827
Bettencourt C et al (2008) Analysis of segregation patterns in Machado-Joseph disease pedigrees. J Hum Genet 53:920–923
Nakano KK et al (1972) Machado disease. A hereditary ataxia in Portuguese emigrants to Massachusetts. Neurology 22:49–55
Rosenberg R, Nyhan W, Bay C, Shore P (1976) Autosomal dominant striatonigral degeneration. A clinical, pathologic, and biochemical study of a new genetic disorder. Neurology 26:14–703
Woods BT et al (1972) Nigro-spino-dentatal degeneration with nuclearophthalmoplegia. A unique and partially treatable clinico-pathological entity. J Neurol Sci 17:149–166
Coutinho P et al (1978) Autosomal dominant system degeneration in Portuguese families of the Azores Islands. A new genetic disorder involving cerebellar, pyramidal, extrapyramidal and spinal cord motor functions. Neurology 28:703–709
Kawaguchi Y et al (1994) CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 8:221–228
Cancel G et al (1995) Marked phenotypic heterogeneity associated with expansion of a CAG repeat sequence at the spinocerebellar ataxia 3/Machado-Joseph disease locus. Am J Hum Genet 57:809–816
Gaspar C et al (1996) Linkage disequilibrium analysis in Machado-Joseph disease patients of different ethnic origins. Hum Genet 98:620–624
Sequeiros J et al (1993) Epidemiology and clinical aspects of Machado-Joseph disease. Adv Neurol 61:139–153
Stevanin G et al (1995) Linkage disequilibrium at the Machado-Joseph disease/spinal cerebellar ataxia 3 locus: evidence for a common founder effect in French and Portuguese-Brazilian families as well as a second ancestral Portuguese-Azorean mutation. Am J Hum Genet 57:1247–1250
Takiyama Y et al (1995) Evidence for inter-generational instability in the CAG repeat in the MJD1 gene and for conserved haplotypes at flanking markers amongst Japanese and Caucasian subjects with Machado-Joseph disease. Hum Mol Genet 4:1137–1146
Gaspar C et al (2001) Ancestral origins of the Machado-Joseph disease mutation: a worldwide haplotype study. Am J Hum Genet 68:523–528
Lima M et al (1998) Origins of a mutation: population genetics of Machado-Joseph disease in the Azores (Portugal). Hum Biol 70:1011–1023
Rosenberg R (1995) Autosomal dominant cerebellar phenotypes: the genotype has settled issue. Neurology 45:1–5
Mittal U et al (2005) Founder haplotype for Machado-Joseph disease in the Indian population: novel insights from history and polymorphism studies. Arch Neurol 62:637–640
Martins S et al (2007) Asian origin for the worldwide-spread mutational event in Machado–Joseph disease. Arch Neurol 64:1502–1508
Martins S et al (2012) Mutational origin of Machado–Joseph disease in the Australian Aboriginal communities of Groote Eylandt and Yirrkala. Arch Neurol 69:746–751
Rosenberg R (1992) Machado-Joseph disease: an autosomal dominant motor system degeneration. Mov Disord 7:193–203
Sudarsky LCP (1995) Machado-Joseph disease. Clin Neuro sci 3:17–22
Lima L et al (1980) Clinical criteria for diagnosis of Machado-Joseph disease: report of a non-Azorena Portuguese family. Neurology 30:319–322
Carvalho DR et al (2008) Homozygosity enhances severity in spinocerebellar ataxia type 3. Pedriatr Neurol 38(4):296–299
Kieling C et al (2007) Survival estimates for patients with Machado-Joseph disease (SCA3). Clin Genet 72(6):543–545
Suite ND et al (1986) Machado-Joseph disease in a Sicilian-American family. J Neurogenet 2(2):177–182
Sakai T et al (1996) Machado-Joseph disease: A proposal of spastic paraplegic subtype. Neurology 46(3):846–847
Pedroso JL et al (2013) Nonmotor and extracerebellar features in Machado-Joseph disease: a review. Mov Disord 28:1200–1208
Raggi A et al (2010) Sleep disorders in neurodegenerative diseases. Eur J Neurol 17:1326–1338
D’Abreu A et al (2009) Sleep symptoms and their clinical correlates in Machado-Joseph disease. Acta Neurol Scand 119:277–280
Pedroso JL et al (2011) Sleep disorders in cerebellar ataxias. Arq Neuropsiquiatr 69:253–257
Pedroso JL et al (2011) Sleep disorders in Machado-Joseph disease: frequency, discriminative thresholds, predictive values, and correlation with ataxia-related motor and non-motor features. Cerebellum 10:291–295
Rub U et al (2008) New insights into the pathoanatomy of spinocerebellar ataxia type 3 (Machado-Joseph disease). Curr Opin Neurol 21:111–116
Schmahmann JD et al (2006) Cognition, emotion and the cerebellum. Brain 129:288–292
Stoodley CJ et al (2010) Evidence for topographic organization in the cerebellum of motor control versus cognitive and affective processing. Cortex 46:831–844
Radvany J et al (1999) Machado Joseph disease of Azorean ancestry in Brazil: the Catarina kindred. Neurological, neuroimaging, psychiatric and neuropsychological findings in the largest known family, the Catarina kindred. Arq Neuropsiquiatr 51:21–30
Zawacki TM et al (2002) Executive and emotional dysfunction in Machado-Joseph disease. Mov Disord 17:1004–1010
Maruff P et al (1996) Cognitive deficits in Machado-Joseph disease. Ann Neurol 40:421–427
Kawai Y et al (2004) Cognitive impairments in Machado-Joseph disease. Arch Neurol 61:1757–1760
Braga-Neto P et al (2011) Cerebellar cognitive affective syndrome in Machado Joseph disease: core clinical features. Cerebellum 11:549–556
Schmitz-Hubsch T et al (2010) Self-rated health status in spinocerebellar ataxia—results from a European multicenter study. Mov Disord 25:587–595
Schmitz-Hubsch T et al (2011) Depression comorbidity in spinocerebellar ataxia. Mov Disord 26:870–876
Braga-Neto P et al (2012) Cognitive deficits in Machado-Joseph disease correlate with hypoperfusion of visual system areas. Cerebellum 11:1037–1044
Braga-Neto P et al (2012) Cognitive and olfactory deficits in Machado-Joseph disease: a dopamine transporter study. Parkinsonism Relat Disord 18:854–858
Cecchin CR et al (2007) Depressive symptoms in Machado-Joseph disease (SCA3) patients and their relatives. Commun Genet 10:19–26
Rodrigues CS et al (2002) Presymptomatic testing for neurogenetic diseases in Brazil: assessing who seeks and who follows through with testing. J Genet Couns 21:101–112
Saute JA et al (2010) Depressive mood is associated with ataxic and non-ataxic neurological dysfunction in SCA3 patients. Cerebellum 9:603–605
Fernandez-Ruiz J et al (2003) Olfactory dysfunction in hereditary ataxia and basal ganglia disorders. Neuroreport 14:1339–1341
Connelly T et al (2003) Olfactory dysfunction in degenerative ataxias. J Neurol Neurosurg Psychiatr 74:1435–1437
Abele M et al (2003). Olfactory dysfunction in cerebellar ataxia and multiple system atrophy. J Neurol 250:1453–1455
Velazquez-Perez L et al (2006) Spinocerebellar ataxia type 2 olfactory impairment shows a pattern similar to other major neurodegenerative diseases. J Neurol 253:1165–1169
Moscovich M et al (2012) Olfactory impairment in familial ataxias. J Neurol Neurosurg Psychiatry 83:970–974
Braga-Neto P et al (2011) Clinical correlates of olfactory dysfunction in spinocerebellar ataxia type 3. Parkinsonism Relat Disord 17:353–356
Coutinho P et al (1986) The peripheral neuropathy in Machado-Joseph disease. Acta Neuropathol (Berl) 71:119–124
Kinoshita A et al (1995) Clinicopathological study of the peripheral nervous system in Machado-Joseph disease. J Neurol Sci 130:48–58
Pedroso JL et al (2011) Is neuropathy involved with restless legs syndrome in Machado-Joseph disease? Eur Neurol 66:200–203
van de Warrenburg BPC et al (2004) Peripheral nerve involvement in spinocerebellar ataxias. Arch Neurol 61:257–261
Franca MC Jr et al (2009) Prospective study of peripheral neuropathy in Machado-Joseph disease. Muscle Nerve 40:1012–1018
Klockgether T et al (1999) Age related axonal neuropathy in spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD). J Neurol Neurosurg Psychiatry 66:222–224
Friedman JH et al (2008) Fatigue and daytime somnolence in Machado-Joseph disease (spinocerebellar ataxia type 3). Mov Disord 23:1323–1324
Franca MC Jr et al (2008) Muscle excitability abnormalities in Machado-Joseph disease. Arch Neurol 65:525–529
Kanai K et al (2003) Muscle cramp in Machado-Joseph disease: altered motor axonal excitability properties and mexiletine treatment. Brain 126:965–973
Franca MC Jr et al (2007) Chronic pain in Machado-Joseph disease: a frequent and disabling symptom. Arch Neurol 64:1767–1770
Yeh TH et al (2005) Autonomic dysfunction in Machado-Joseph disease. Arch Neurol 62:630–636
Franca MC Jr et al (2010) Clinical correlates of autonomic dysfunction in patients with Machado-Joseph disease. . Acta Neurol Scand 121:422–425
Pradhan C et al (2008) Spinocerebellar ataxias type 1, 2 and 3: a study of heart rate variability. Acta Neurol Scand 117:337–342
Yamanaka Y et al (2012) Cutaneous sympathetic dysfunction in patients with Machado-Joseph disease. Cerebellum 11:1057–1060
van Gaalen J et al (2011) Movement disorders in spinocerebellar ataxias. Mov Disord 26:792–800
Schols L et al (2000) Extrapyramidal motor signs in degenerative ataxias. Arch Neurol 57:1495–1500
Schmitz-Hubsch T et al (2008) Spinocerebellar ataxia types 1, 2, and 6. Disease severity and nonataxia symptoms. Neurology 71:982–989
Tuite PJ et al (1995) Dopa- responsive parkinsonism phenotype of Machado-Joseph disease: confirmation of 14q CAG expansion. Ann Neurol 38:684–687
Bettencourt C et al (2011) Parkinsonism pheno- type in Machado-Joseph disease (MJD/SCA3): a two-case report [serial online]. BMC Neurol 11:131
Socal MP et al (2009) Intrafamilial variability of Parkinson phenotype in SCAs: novel cases due to SCA2 and SCA3 expansions. Parkinsonism Relat Disord 15:374–378
Gwinn-Hardy K et al (2001) Spinocerebellar ataxia type 3 phenotypically resembling Parkinson disease in a black family. Arch Neurol 58:296–299
Subramony SH et al (2002) Ethnic differences in the expression of neurodegenerative disease: Machado–Joseph disease in Africans and Caucasians. Mov Disord 17:1068–1071
Lu CS et al (2004) The parkinsonian phenotype of spinocerebellar ataxia type 3 in a Taiwanese family. Parkinsonism Relat Disord 10:369–373
Pedroso JL et al (2012) Transcranial sonography: Brazilian experience. Arq Neuropsiquiatr 70:313–314
Teive HAG et al (2012) Spinocerebellar ataxias—Genotype-phenotype correlation in 104 Brazilian families. Clinics (Sao Paulo) 67:443–449
Siebert M et al (2012) Glucocerebrosidase gene variants in parkinsonism patients with Machado-Joseph/spinocerebellara ataxia 3. Parkinsonism Relat Disord 18:185–190
Pedroso JL et al (2011) Akathisia: an unusual movement disorder in Machado-Joseph disease. Parkinsonism Relat Disord 17:12–13
Horimoto Y et al (2011) Longitudinal study on MRI intensity changes of Machado-Joseph disease: correlation between MRI findings and neuropathological changes. J Neurol:1657–1664
Imon Y et al (1998) A necropsied case of Machado-Joseph disease with a hyperintense signal of transverse pontine fibres on long TR sequences of magnetic resonance images. J Neurol Neurosurg Psychiatry 64:140–141
Murata Y et al (1998) Characteristic magnetic resonance imaging findings in Machado-Joseph disease. Arch Neurol 55:33–37
Yamada S et al (2005) Linear high intensity area along the medial margin of the internal segment of the globus pallidus in Machado-Joseph disease patients. J Neurol Neurosurg Psychiatry 76:573–575
Lee YC et al (2009) The ‘hot cross bun’ sign in the patients with spinocerebellar ataxia. Eur J Neurol 16:513–516
De Oliveira MS et al (2010) MRI-texture analysis of corpus callosum, thalamus, putamen, and caudate in Machado-Joseph disease. J Neuroimaging 22:46–52
D’Abreu A et al (2012) Neocortical atrophy in Machado-Joseph disease: a longitudinal neuroimaging study. J Neuroimaging 22:285–291
de Rezende TJ et al (2015) Cerebral cortex involvement in Machado-Joseph disease. Eur J Neurol 11:277– 83 (e23–24)
Schulz JB et al (2010) Visualization, quantification and correlation of brain atrophy with clinical symptoms in spinocerebellar ataxia types 1, 3 and 6. Neuroimage 49:158–68
Reetz K et al (2013) Ataxia Study Group Investigators. Genotype-specific patterns of atrophy progression are more sensitive than clinical decline in SCA1, SCA3 and SCA6. Brain 136:905–17
Guimarães RP (2013) A multimodal evaluation of microstructural white matter damage in spinocerebellar ataxia type 3. Mov Disord 28:1125–1132
D’Abreu A et al (2009) Axonal dysfunction in the deep white matter in Machado-Joseph disease. J Neuroimaging 19:9–12
Wang PS et al (2012) Association between proton magnetic resonance spectroscopy measurements and CAG repeat number in patients with spinocerebellar ataxias 2, 3, or 6. PLoS One 7:e47479
Lirng JF et al (2012) Differences between spinocerebellar ataxias and multiple system atrophy-cerebellar type on proton magnetic resonance spectroscopy. PLoS One 7:e47925
Jacobi H et al (2013) Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data. Lancet Neurol 12:630
Nunes MB, Martinez AR, Rezende TJ et al (2015) Dystonia in Machado–Joseph disease: Clinical profile, therapy and anatomical basis. Parkinsonism Relat Disord 21:1441–1447
Etchebehere EC et al (2001) Brain single- photon emission computed tomography and magnetic resonance imaging in Machado-Joseph disease. Arch Neurol 58:1257–1263
Taniwaki T et al (1997) Positron emission tomography (PET) in Machado-Joseph disease. J Neurol Sci 145:63–67
Soong BW et al (1998) Positron emission tomography in asymptomatic gene carriers of Machado-Joseph disease. J Neurol Neurosurg Psychiatry 64:499–504
Ogawa M (2004) Pharmacological treatments of cerebellar ataxia. Cerebellum 3:107–111
Correia M et al (1995) Evaluation of the effect of sulphametoxazole and trimethoprim in patients with Machado-Joseph disease. Rev Neurol 23:632–634
Buhmann C et al (2003) Dopaminergic response in Parkinsonian phenotype of Machado–Joseph disease. Mov Disord 18:219–221
Wilder-Smith E et al (2003) Spinocerebellar ataxia type 3 presenting as an L-DOPA responsive dystonia phenotype in a Chinese family. J Neurol Sci 213:25–28
Nandagopal R et al (2004) Dramatic levodopa responsiveness of dystonia in a sporadic case of spinocerebellar ataxia type 3. Postgrad Med J 80:363–365
D’Abreu A et al (2010) Caring for Machado- Joseph disease: current understanding and how to help patients. Relat Disord 16:2–7
Zesiewicz TA et al (2012) A randomized trial of varenicline (Chantix) for the treatment of spinocerebellarataxia type 3. Neurology 78:545–550
Azulay JP et al (1994) Contrast sensitivity improvement with sulfamethoxazole and trimethoprim in a patient with Machado-Joseph disease without spasticity. J Neurol Sci 123:95–99
Mello KA et al (1988) Effect of sulfamethoxazole and trimethoprim on neurologic dysfunction in a patient with Joseph’s disease. Arch Neurol 45:210–213
Sakai T et al (1995) Sulfamethoxazoletrimethoprim double-blind, placebo-controlled, crossover trial in Machado-Joseph disease: sulfamethoxazole-trimethoprim increases cerebrospinal fluid level of biopterin. J Neural Transm Gen Sect 102:159–172
Thorsten Schulte RM (2001) Double-blind crossover trial of trimethoprim-sulfamethoxazole in spinocerebellar ataxia type 3/Machado-Joseph disease. Arch Neurol 58:1451–1457
Saute JA et al (2014) A Randomized, phase 2 clinical trial of lithium carbonate in Machado-Joseph disease. Mov Disord 29:568–573
Kieling C et al (2008) A neurological examination score for the assessment of spinocerebellar ataxia 3 (SCA3). Eur J Neurol 15:371–376
Schmitz-Hübsch T et al (2006) Scale for the assessment and rating of ataxia. Neurology 66:1717–1720
Du Montcel ST et al (2008) Composite cerebellar functional severity score: Validation of a quantitative score of cerebellar impairment. Brain 131:1352–1361
Saute JA et al (2015) Planning future clinical trials in Machado Joseph disease: Lessons from a phase 2 trial. J Neurol Sci 358:72–76
Monte TL et al (2003) Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study. Acta Neurol Scand 107:207–210
Takei A et al (2004) Effects of tandospirone on “5-HT1A receptor-associated symptoms” in patients with Machado-Josephe disease: an open-label study. Clin Neuropharmacol 27:9–13
Liu C-S et al (2005) Clinical and molecular events in patients with Machado–Joseph disease underlamotrigine therapy. Acta Neurol Scand 111:385–390
Conflict of Interest:
Nuno Mendonça is a full time AbbVie Deutschland GmbH & Co. KG employee and may hold AbbVie stock and/or stock options.
The content of this work is not associated with the author responsibilities as an AbbVie employee.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Mendonça, N., França, M.C., Gonçalves, A.F., Januário, C. (2018). Clinical Features of Machado-Joseph Disease. In: Nóbrega, C., Pereira de Almeida, L. (eds) Polyglutamine Disorders. Advances in Experimental Medicine and Biology, vol 1049. Springer, Cham. https://doi.org/10.1007/978-3-319-71779-1_13
Download citation
DOI: https://doi.org/10.1007/978-3-319-71779-1_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-71778-4
Online ISBN: 978-3-319-71779-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)